MEDINA is a drug discovery organization and a partner site of the European research infrastructure EU-OPENSCREEN (www.eu-openscreen.eu). Leveraging our drug discovery expertise, the potential of our natural product libraries and the high throughput screening and...
MEDINA is leader in Drug Discovery from Microbial Natural Product Libraries and internal High Throughput Screening (HTS) programs are focused on strategic therapeutic areas: Infectious and Parasitic Diseases, Oncology and Neurodegeneration.
MEDINA joins the global COVID-19 research effort looking for new therapeutics and diagnostic solutions for SARS-CoV-2.
Click on above image and keep up to date with our latest news.
MEDINA offers Contract Research services for Drug Discovery and other high value biotechnology areas to academic research and industrial organizations.
MEDINA discovers bio-active molecules, drug leads for unmet medical needs and high value biotechnological products.
We are exclusive owners of one of the world´s largest Microbial Collections (190,000 microbial strains), and Natural Products Libraries (over 135,000 extracts & fractions).
SUBSCRIBE TO OUR NEWSLETTER
New article by Fundacion MEDINA in collaboration with the Marine Biotechnology Department at the Stazione Zoologica Anton Dohrn, Naples, and the Department of Chemical, Biological, Pharmaceutical and Environmental Sciences (ChiBioFarAm) of the University of Messina:...
BSP meeting Trypanosomiasis & Leishmaniasis Symposium: Novel Advances in Basic and Applied Research. March 8 – 11, Granada- Spain.
Dr. Freddie Annang, a specialist in drug discovery against parasitic diseases from Fundación MEDINA, attended the BSP meeting entitled “Trypanosomiasis & Leishmaniasis Symposium: Novel Advances in Basic and Applied Research” which took place in Granada from the...